PE20000021A1 - Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p - Google Patents

Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p

Info

Publication number
PE20000021A1
PE20000021A1 PE1998001112A PE00111298A PE20000021A1 PE 20000021 A1 PE20000021 A1 PE 20000021A1 PE 1998001112 A PE1998001112 A PE 1998001112A PE 00111298 A PE00111298 A PE 00111298A PE 20000021 A1 PE20000021 A1 PE 20000021A1
Authority
PE
Peru
Prior art keywords
disorders
alkyl
haloalkyl
compound
emergency
Prior art date
Application number
PE1998001112A
Other languages
English (en)
Inventor
Kunio Satake
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20000021A1 publication Critical patent/PE20000021A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6, HALOALQUILO C1-C6 o FENILO; R3 ES H o HALOGENO; R4 Y R5 SON H, ALQUILO C1-C6 o HALOALQUILO C1-C6; n ES 1-3. SON COMPUESTOS PREFERIDOS (2S,3S)-3-[(1R)-(6-METOXI-1-METIL-1-TRIFLUOROMETILISOCROMAN-7-IL]METILAMINO-2-FENILPIPERIDINA; (2S,3S)-3-[(3R)-(6-METOXI)-3-METIL-3-TRIFLUOROMETIL-1,3-DIHIDROBENZOFURAN-5-IL)METILAMINO-2-FENILPIPERIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN COMPUESTO DE FORMULA III, DONDE W ES H o Q(O=)C-; Q ES H, ALQUILO C1-C6, HALOALQUILO C1-C6. EL COMPUESTO I ES UN ANTAGONISTA DE LA SUSTANCIA P (PEPTIDO DE LA TAQUICININA) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, TRASTORNOS ALERGICOS, ANGIOGENESIS, TRASTORNOS GASTROINTESTINALES, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDADES INFLAMATORIAS, EMESIS, INCONTINENCIA URINARIA, DOLOR, MIGRANA, TRASTORNOS DE ANSIEDAD SEVERA, TRASTORNOS DE ESTRES, QUEMADURAS SOLARES, TRASTORNOS PROVOCADOS POR HELICOBACTER PILORI, DISFUNCION SEXUAL
PE1998001112A 1997-11-19 1998-11-16 Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p PE20000021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9701466 1997-11-19

Publications (1)

Publication Number Publication Date
PE20000021A1 true PE20000021A1 (es) 2000-02-25

Family

ID=11004634

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001112A PE20000021A1 (es) 1997-11-19 1998-11-16 Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p

Country Status (39)

Country Link
US (2) US20030208079A1 (es)
EP (1) EP1032571B1 (es)
JP (2) JP3394239B2 (es)
KR (1) KR100366902B1 (es)
CN (1) CN1173974C (es)
AP (1) AP909A (es)
AR (1) AR016422A1 (es)
AT (1) ATE219078T1 (es)
AU (1) AU734218B2 (es)
BG (1) BG63969B1 (es)
CA (1) CA2310627C (es)
CO (1) CO4771153A1 (es)
CZ (1) CZ297315B6 (es)
DE (1) DE69806045T2 (es)
DK (1) DK1032571T3 (es)
DZ (1) DZ2655A1 (es)
EA (1) EA002621B1 (es)
ES (1) ES2177058T3 (es)
HR (1) HRP20000313B1 (es)
HU (1) HUP0101112A3 (es)
ID (1) ID24240A (es)
IL (1) IL135631A0 (es)
IS (1) IS2202B (es)
MA (1) MA26567A1 (es)
MY (1) MY120558A (es)
NO (2) NO20002544L (es)
NZ (1) NZ503912A (es)
OA (1) OA11380A (es)
PA (1) PA8463001A1 (es)
PE (1) PE20000021A1 (es)
PL (1) PL193484B1 (es)
PT (1) PT1032571E (es)
RS (1) RS49792B (es)
SK (1) SK283460B6 (es)
TN (1) TNSN98210A1 (es)
TR (1) TR200001463T2 (es)
TW (1) TW426667B (es)
UA (1) UA59417C2 (es)
WO (1) WO1999025714A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
JP2002544128A (ja) * 1999-05-06 2002-12-24 ファイザー・プロダクツ・インク 置換ベンゾラクタム化合物
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
HRP20010861A2 (en) * 1999-05-21 2003-04-30 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
AU7557000A (en) * 1999-10-07 2001-05-10 Hisamitsu Pharmaceutical Co. Inc. Piperidine derivatives
DK1095939T3 (da) * 1999-10-18 2004-04-13 Pfizer Prod Inc Fremgangsmåde til fremstilling af cykliske piperidinylaminomethyltrifluormethyletherforbindelser
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
ATE332897T1 (de) 2001-08-30 2006-08-15 Pfizer Prod Inc Verfahren zur herstellung von 2-(4-alkyl-1- piperazinyl)-benzaldehyd und -benzylidenyl- derivaten durch nucleophile substitution von 2- fluorobenzaldehyd mit 4-alkyl-1-piperazinen in wasser als lösungsmittel
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
EP1536816A4 (en) * 2002-08-27 2008-08-06 Immuneregen Biosciences Inc IMPROVING THE EFFECTS OF CIGARETTE SMOKE
US6911544B2 (en) * 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102008000891A1 (de) 2008-03-31 2009-10-01 Robert Bosch Gmbh Schutzsystem für Werkzeugmaschinen
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
US5886011A (en) * 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
MX9800187A (es) * 1995-07-07 1998-05-31 Pfizer Compuestos de benzolactama substituidos como antagonistas de la substancia p.
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6329396B1 (en) * 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
HRP20010861A2 (en) * 1999-05-21 2003-04-30 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
DK1095939T3 (da) * 1999-10-18 2004-04-13 Pfizer Prod Inc Fremgangsmåde til fremstilling af cykliske piperidinylaminomethyltrifluormethyletherforbindelser

Also Published As

Publication number Publication date
ATE219078T1 (de) 2002-06-15
IL135631A0 (en) 2001-05-20
CA2310627A1 (en) 1999-05-27
PA8463001A1 (es) 2000-09-29
JP2001523680A (ja) 2001-11-27
AU9454998A (en) 1999-06-07
TW426667B (en) 2001-03-21
HRP20000313A2 (en) 2000-12-31
JP3394239B2 (ja) 2003-04-07
JP2003040777A (ja) 2003-02-13
PL193484B1 (pl) 2007-02-28
UA59417C2 (uk) 2003-09-15
EA002621B1 (ru) 2002-06-27
YU29400A (sh) 2003-02-28
DK1032571T3 (da) 2002-07-15
HUP0101112A2 (hu) 2002-05-29
TNSN98210A1 (fr) 2005-03-15
AP909A (en) 2000-12-04
CN1173974C (zh) 2004-11-03
EP1032571B1 (en) 2002-06-12
EP1032571A1 (en) 2000-09-06
HRP20000313B1 (en) 2002-04-30
AU734218B2 (en) 2001-06-07
OA11380A (en) 2004-01-27
CO4771153A1 (es) 1999-04-30
CZ297315B6 (cs) 2006-11-15
CN1279681A (zh) 2001-01-10
NO20042879L (no) 2000-07-17
SK7232000A3 (en) 2001-09-11
US20030208079A1 (en) 2003-11-06
MY120558A (en) 2005-11-30
DE69806045D1 (en) 2002-07-18
CA2310627C (en) 2005-08-09
BG104437A (en) 2001-02-28
ID24240A (id) 2000-07-13
ES2177058T3 (es) 2002-12-01
HUP0101112A3 (en) 2002-06-28
PL340642A1 (en) 2001-02-12
AR016422A1 (es) 2001-07-04
NZ503912A (en) 2002-09-27
DZ2655A1 (fr) 2003-03-22
NO20002544D0 (no) 2000-05-18
AP9801402A0 (en) 1998-12-31
WO1999025714A1 (en) 1999-05-27
SK283460B6 (sk) 2003-08-05
PT1032571E (pt) 2002-09-30
RS49792B (sr) 2008-06-05
TR200001463T2 (tr) 2000-12-21
KR100366902B1 (ko) 2003-01-09
HK1033313A1 (en) 2001-08-24
DE69806045T2 (de) 2002-11-14
US20050171354A1 (en) 2005-08-04
IS2202B (is) 2007-02-15
IS5470A (is) 2000-04-26
MA26567A1 (fr) 2004-12-20
BG63969B1 (bg) 2003-08-29
NO20002544L (no) 2000-07-17
EA200000432A1 (ru) 2000-12-25
CZ20001834A3 (cs) 2001-07-11

Similar Documents

Publication Publication Date Title
PE20000021A1 (es) Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20040120A1 (es) Derivados de quinolina como antagonistas de npy
EA200000360A1 (ru) Оральные композиции левосимендана
PE20030610A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides
PE20020407A1 (es) Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1
DK1778677T3 (da) Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
ES2154605A1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
EA200400454A1 (ru) Мускариновые агонисты
PE20020905A1 (es) Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip
MA29336B1 (fr) Derives d'aryl-1,4-pyrazine substitues
PE20020436A1 (es) Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20060557A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas como antagonistas de los receptores trpv1
ATE239722T1 (de) Benzofurylpiperazine als serotonin-agonisten

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed